Diagnosis and Treatment of Metastatic Bone Disease Using MRI

Unlike soft-tissue or solid organ metastases, bone lesions have long been considered non-measurable due to the limited sensitivity and quantitative precision of standard imaging techniques (SS, radiography, and CT). This article evaluates the limitations of these conventional modalities and the potential of PET, while primarily focusing on magnetic resonance imaging (MRI). We propose morphological and quantitative methodologies for assessing treatment response in bone marrow using anatomical MRI and review recent advancements in functional imaging, specifically dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) [1].

Assessing therapeutic response is fundamental to clinical decision-making, guiding determinations regarding the continuation, modification, or cessation of routine regimens and investigational agents. While morphological and functional imaging are pivotal for evaluating primary tumors and soft-tissue metastases-supported by validated quantitative metrics such as RECIST and WHO criteria [2], no comparable standardized tools currently exist for osseous lesions. Consequently, the assessment of disease progression in bone relies heavily on 'skeletal-related events' (SREs), a metric with well-documented limitations [3]. There is a critical need for robust clinical endpoints that serve as prognostic indicators for disease trajectory, complication risks, and survival outcomes. Ultimately, while treatment response is a known determinant of survival, this prognostic link remains elusive in patients with predominant or exclusive bone involvement due to the paucity of accurate monitoring techniques

For years, the lack of sensitivity, specificity, and measurable parameters in skeletal scintigraphy (SS), radiography, and computed tomography (CT) has rendered bone lesions 'non-measurable,' in sharp contrast to the standardized evaluation of visceral and soft-tissue neoplasms. This review critically examines the limitations of such conventional modalities and the emerging role of positron emission tomography (PET), yet centrally emphasizes the diagnostic superiority of magnetic resonance imaging (MRI) [4]. It delineates practical morphological and quantitative protocols for monitoring therapeutic efficacy in bone marrow via anatomical MRI and further explores the integration of novel functional techniques, including dynamic contrast-enhanced (DCE) imaging and diffusion-weighted imaging (DWI).

Predicated on its widespread availability and economic viability, skeletal scintigraphy (SS) has long been the cornerstone of staging for osteotropic neoplasms. The modality employs a diphosphonate-bound 99m-technetium radiotracer to target sites of osteoblastic proliferation. This physiological basis, however, renders the technique less sensitive to predominantly osteolytic pathologies. Modern cross-sectional and functional imaging (MRI and PET) demonstrates superior detection rates, identifying lesions in a significant subset of SS-negative patients. This diagnostic discordance has profound clinical implications, necessitating the use of high-sensitivity modalities to confirm the absence of metastases prior to initiating curative interventions [5-6].

Conventional radiography remains the frontline modality for investigating localized symptomatology and diagnosing pathological fractures. Nevertheless, its application in routine metastatic surveillance is negligible—excluding cases of multiple myeloma (MM) due to significant limitations in sensitivity. Notably, the detection of osteolytic trabecular lesions requires a mineral depletion of 30–75% [7]. In current clinical practice, radiographic imaging is therefore restricted to the clarification of equivocal scintigraphic data, the morphological differentiation of osteolytic versus osteoblastic activity, and the evaluation of impending structural compromise.

Plain radiography is unsuitable for the systematic evaluation of treatment response due to significant diagnostic limitations. Radiographic indicators of healing such as peripheral sclerosis, re-ossification, and increased density-are frequently ambiguous, absent, or subject to substantial temporal latency despite clinical improvement [8-9]. In the context of multiple myeloma (MM), while radiographs remain integral to the Durie and Salmon staging system, the substitution of this modality with MRI is increasingly advocated to facilitate the early detection of high-risk or advanced disease [10]. Furthermore, radiographic skeletal surveys offer limited utility for longitudinal follow-up, as lytic defects often persist morphologically even when MRI demonstrates clear evidence of therapeutic response [11].

The main objectives of magnetic resonance imaging (MRI) in the management of metastatic bone disease are the early detection, accurate characterization, and longitudinal quantification of osseous lesions. Unlike conventional radiography or scintigraphy, MRI offers superior contrast resolution, enabling the identification of intramedullary metastases prior to cortical destruction. This high sensitivity facilitates precise staging and the differentiation of malignant deposits from benign etiologies or infection. Furthermore, advanced functional MRI sequences, such as diffusion-weighted imaging (DWI), aim to provide quantitative biomarkers for monitoring therapeutic response, allowing clinicians to distinguish active tumor viability from post-treatment necrosis and fibrosis, thereby guiding timely oncologic decision-making.

1. Patient and Methods
   • Computed Tomography

Historically, radiation safety constraints have restricted computed tomography (CT) to targeted anatomical assessments, precluding its use for systematic skeletal screening. However, the emergence of multidetector CT (MDCT) combined with advanced dose-reduction protocols may prompt a reevaluation of this paradigm [11]. While CT demonstrates superior diagnostic sensitivity compared to plain radiography and offers simultaneous evaluation of adjacent soft tissues, it remains less sensitive than MRI or PET [12-13]. Furthermore, CT evaluations of therapeutic response can be confounded by false-positive findings; specifically, the osteosclerotic remineralization of previously lytic or occult lesions may mimic progression. This phenomenon is frequently elucidated through the correlation of pre- and post-treatment PET/CT data, which distinguishes metabolic response from morphological changes (Figure 1).

Computed tomography (CT) is not typically designated as the primary modality for longitudinal monitoring of bone lesions. Nevertheless, skeletal data is frequently acquired as a byproduct of routine thoraco-abdomino-pelvic CT scans performed for visceral staging and follow-up. These examinations provide incidental but valuable visualization of the axial skeleton, particularly the vertebral column and pelvic girdle. The diagnostic yield of such opportunistic screening can be maximized through the application of optimized acquisition and reconstruction protocols. definitive indicators of disease progression include the dimensional expansion of lytic defects, the emergence of osteolysis within previously sclerotic foci, and the enlargement of associated soft tissue masses. Conversely, findings such as morphological stability, the development of sclerosis, or the appearance of new sclerotic foci must be interpreted with caution and are generally excluded from formal response criteria due to their ambiguous clinical significance [14].

• Positron Emission Tomography and PET-CT

Positron emission tomography (PET) allows comprehensive whole-body imaging with simultaneous assessment of all major organ systems. The integration of PET with computed tomography (CT), and more recently with magnetic resonance imaging (MRI) in hybrid imaging platforms, enables the fusion of metabolic and functional data derived from PET with the precise anatomical localization afforded by CT or MRI. During therapeutic follow-up, these modalities yield distinct yet complementary insights into disease behavior. Lesions responding to treatment typically demonstrate reduced tracer uptake on PET images, accompanied by increased attenuation on CT scans reflecting therapy-induced osteoblastic activity. In contrast, disease progression is characterized by heightened metabolic activity on PET and the development or worsening of osteolytic changes on CT imaging.

The most widely utilized radiotracer, 18F-fluorodeoxyglucose (18F-FDG), serves as a surrogate marker for glucose metabolism and transport physiological processes upregulated in various neoplasms but also present in certain benign conditions. This modality facilitates whole-body qualitative assessment, enabling the simultaneous visualization of primary tumors and metastatic sites. Quantitatively, metabolic activity is characterized via the standardized uptake value (SUV), a metric normalized for injected dose and patient body weight within a defined region of interest. Consequently, therapeutic response is evaluated through longitudinal comparison of these qualitative and quantitative parameters [15]. 18F-FDG PET is currently the preferred modality for the staging and surveillance of malignancies such as lymphoma, melanoma, and carcinomas of the lung, breast, and head and neck [16-18], demonstrating particular efficacy in monitoring breast cancer bone metastases [19]. However, the routine clinical implementation of PET for response assessment requires further standardization, specifically regarding the definition of quantitative cutoffs for response versus progression, optimal follow-up intervals, and the precise role of CT within hybrid PET/CT protocols [20].

The diagnostic utility of 18F-fluorodeoxyglucose (18F-FDG) is not universal; specific malignancies notably prostate, neuroendocrine, and certain bronchial carcinomas as well as osteosclerotic metastases, exhibit significantly lower avidity for FDG compared to osteolytic lesions [14]. Consequently, alternative radiotracers targeting non-glycolytic metabolic pathways have been developed for these low-affinity tumors. Although the clinical implementation of these agents is often constrained by complex synthesis requirements and short half-lives, tracers such as 11C/18F-choline and 11C-acetate have demonstrated promising efficacy, particularly in the evaluation of prostate cancer. Furthermore, 18F-fluoride represents a significant diagnostic advancement; this tracer targets regions of high osteoblastic turnover, incorporating into the bone matrix as fluoroapatite. This mechanism yields images analogous to skeletal scintigraphy (SS) but with superior contrast and spatial resolution, resulting in enhanced diagnostic sensitivity. Additionally, novel tracers targeting specific tumor receptors are currently under development for hormone-receptor-positive and neuroendocrine neoplasms.

• Magnetic Resonance Imaging

Conventional imaging modalities specifically radiography, skeletal scintigraphy (SS), and computed tomography (CT)—are constrained by significant diagnostic latency. These techniques rely on the secondary activation of osteoclasts and osteoblasts to generate visible structural changes, detecting lesions weeks or months after the initial seeding of tumor cells. In contrast, magnetic resonance imaging (MRI) is sensitive to the incipient cellular infiltration of the bone marrow compartment, enabling the identification of pathology prior to any reactive remodeling of the trabecular or cortical bone matrix [21]. Consequently, the diagnostic superiority of MRI over SS and radiography has been extensively validated across a spectrum of solid tumors and hematological malignancies (Figure 2) [21- 22].

Due to its broad accessibility, high reproducibility, non-ionizing nature, and capacity for whole-body assessment (WB-MRI), magnetic resonance imaging has emerged as the preferred modality for the detection and characterization of skeletal neoplasms. MRI is currently advocated for both initial staging and the longitudinal evaluation of therapeutic response through a combination of qualitative and quantitative metrics. Furthermore, the integration of standard anatomical sequences with advanced functional techniques specifically dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI) enhances diagnostic precision. These functional tools are particularly valuable for assessing therapeutic efficacy during the early phases of treatment [23].

• Setting of the study

This retrospective study was conducted at a tertiary academic referral center between January 2022 and December 2024, patients confirmed metastatic bone disease evaluated using a 1.5-Tesla MRI system. The protocol adhered to the Declaration of Helsinki, with approval granted by the Institutional Review Board (IRB).